Sanofi’s Sarclisa (isatuximab-irfc) Receives the US FDA’s Approval for Relapsed Refractory Multiple Myeloma

 Sanofi’s Sarclisa (isatuximab-irfc) Receives the US FDA’s Approval for Relapsed Refractory Multiple Myeloma

Sanofi’s Sarclisa (isatuximab-irfc) Receives the US FDA’s Approval for Relapsed Refractory Multiple Myeloma

Shots:

  • The approval is based on P-III ICARIA-MM study Sarclisa (IV, 10mg/kg) + pomalidomide + dexamethasone (pom-dex) vs pom-dex as monothx. in patients with RRMM, prior treated with at least two therapies including lenalidomide and a proteasome inhibitor
  • The P-III ICARIA-MM study results: improvement in PFS (11.53 vs 6.47); improvement in ORR (60.4% vs 35.3%)
  • Sarclisa is mAb targeting CD38 receptor on MM cells, act by inducing apoptosis & immunomodulatory activity and has received FDA & EMA’s ODD with its anticipated availability in the US soon

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post